TOS 2022 Webinar on Personalizing Obesity Management
Continuing Medical Education
Information for Learners

Credit for this course may not exceed 3.25 credits when both the live and enduring material activity format credits are combined.

Live Course Accreditation and Credit for Physicians

The Obesity Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Obesity Society designates this live activity for a maximum of 3.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

On-Demand Course Accreditation and Credit for Physicians

The Obesity Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Obesity Society designates enduring material for a maximum of 3.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Important Dates for On-Demand Course (Enduring Material)

Date of Release: March 3, 2022
Date of Termination: March 1, 2025

Learning Objectives

1. Participants will be able to personalize their approach to obesity management by learning to obtain and consider their patient's individual history and narrative.

2. Participants will learn to consider psychological drivers and barriers in their patients with obesity.

3. Participants will be able to stage individual patients based on severity of their disease.

4. Participants will be able to better match treatments to individual patients based on their personal needs and expectations.

Commercial Support

No commercial support was received for this activity.

Faculty and Planning Committee Disclosure Information

The Obesity Society adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities1 (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

The Obesity Society asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relevant relationships with ineligible companies. This information is disclosed to CME activity participants. The Obesity Society has procedures to mitigate all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals or devices is being discussed. TOS requires additional disclosures beyond the ACCME definition of an ineligible company. These include food, weight loss, and supplement industry disclosures. In the list below, the nature of the relationship and company are followed by the industry of that company.

1 An ineligible company as defined by the ACCME is one that is not eligible for ACCME accreditation, in other words those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Examples of such organizations include: 1) Advertising, marketing, or communication firms whose clients are ineligible companies, 2) Bio-medical startups that have begun a governmental regulatory approval process, 3) Compounding pharmacies that manufacture proprietary compound, 4) Device manufacturers or distributors, 5) Diagnostic labs that sell proprietary products, 6) Growers, distributors, manufacturers or sellers of medical foods and dietary supplements, 7) Manufacturers of health-related wearable products, 8) Pharmaceutical companies or distributors, 9) Pharmacy benefit managers, 10) Reagent manufacturers or sellers. Reference: [https://accme.org/faq/what-accmes-definition-ineligible-company](https://accme.org/faq/what-accmes-definition-ineligible-company)
Speaker Disclosures:

Louis J. Aronne, MD, FACP, FTOS, DABOM
Consultant/Advisory Board Member relationship with Alimmune (Pharmaceuticals); Atria (Pharmaceuticals); Jazz Pharmaceuticals (Pharmaceuticals); Pfizer (Pharmaceuticals); Optum (Pharmaceuticals); Senda Biosciences (Pharmaceuticals); and Versanis (Pharmaceuticals).
Consultant/Advisory Board Member, Research Funding, and Equity Interests relationship with Gelesis (Pharmaceuticals).
Consultant/Advisory Board Member, Equity Interests, and Board of Directors relationship with Jamieson Wellness (Pharmaceuticals).
Consultant/Advisory Board Member, Research Funding relationship with Janssen Pharmaceuticals (Pharmaceuticals); Novo Nordisk (Pharmaceuticals); and Eli Lilly (Pharmaceuticals).
Research Funding relationship with Astra Zeneca (Pharmaceuticals).
Equity Interests and a Board of Directors' Member relationship Intellihealth (TOS Weight Management Telemedicine conflict - Not an ACCME conflict).

Denise Campbell-Scherer, MD, PhD, PhD, CCFP, FCFP
Consulting Fee relationship with Pfizer (Pharmaceuticals). 
Research grant to understand obesity in vulnerable people relationship with NOVAD (Novo Nordisk Pharmaceuticals & government consortium).

Robert F. Kushner, MD
No relevant financial relationships

Arya M. Sharma, MD, DSc (hon), FRCP
Consulting Fee relationship with Novo Nordisk (Pharmaceuticals); Boehringer Ingelheim (Pharmaceuticals); and Johnson & Johnson (Medical Device).

Stephanie Sogg, PhD, FTOS
No relevant financial relationships

Sean Wharton, MD, FRCPC, PharmD
Speakers Bureau relationship with Novo Nordisk (Pharmaceuticals); Bausch Health Canada (Pharmaceuticals); and Eli Lilly (Pharmaceuticals).

Planner Disclosures:

Arya M. Sharma, MD, DSc (hon), FRCP
Consulting Fee relationship with Novo Nordisk (Pharmaceuticals); Boehringer Ingelheim (Pharmaceuticals); and Johnson & Johnson (Medical Device).

Reviewer Disclosures: No members of the TOS CME Oversight Committee, charged with the resolution of all relevant conflicts of interest, had any relevant financial relationships while serving on the committee.

Bibliography

2. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.  

3. https://www.guidelines.co.uk/public-health/nice-obesity-guideline/252547.article  
Obesity: identification, assessment and management  
Published date: 27 November 2014 (amended February 2021) by The National Institute for Health and Care Excellence (NICE).

4. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society  
2014 Jun 24;129(25 Suppl 2):S139-40. DOI: 10.1161/01.cir.0000437739.71477.ee  PMID: 24222017

Disclaimer

These materials and all other materials provided in conjunction with continuing medical education activities are intended solely for the purposes of supplementing continuing medical education programs for qualified health care professionals. Anyone using the materials assumes full responsibility and all risk for their appropriate use. The Obesity Society makes no warranties or representations whatsoever regarding the accuracy, completeness, currentness, noninfringement, merchantability or fitness for a particular purpose of the materials. In no event will The Obesity Society be liable to anyone for any decision made or action taken in reliance on the materials. In no event should the information in the materials be used as a substitute for professional care.

This document was last updated February 24, 2022.